Comparing the suitability of autodock, gold and glide for the docking and predicting the possible targets of Ru(II)-based complexes as anticancer agents

Molecules

Volumn 18, Issue 4, 2013, Pages 3760-3778

  Adeniyi, Adebayo A ^a   Ajibade, Peter A ^a  

^a UNIVERSITY OF FORT HARE   (South Africa)

Author keywords

Binding site interaction; Cancer receptors; Docking; Meta based complexes; Unusual ligands

Indexed keywords

4-CYMENE; ANTINEOPLASTIC AGENT; COORDINATION COMPOUND; GOLD; LIGAND; PARA CYMENE; RUTHENIUM; TERPENE;

ARTICLE; BINDING SITE; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; HUMAN; MACROMOLECULE;

ANTINEOPLASTIC AGENTS; BINDING SITES; COMPUTATIONAL BIOLOGY; COORDINATION COMPLEXES; GOLD; HUMANS; LIGANDS; MACROMOLECULAR SUBSTANCES; MOLECULAR STRUCTURE; MONOTERPENES; RUTHENIUM;

EID: 84876779931     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18043760     Document Type: Article

References (44)

1. Sava, G.; Bergamoa, A.; Dyson, P.J. Metal-based antitumour drugs in the post-genomic era: What comes next? Dalton Trans. 2011, 40, 9069-9075.
2. Allardyce, C.S.; Dorcier, A.; Scolaro, C.; Dyson P.J. Development of organometallic (organo-transition metal) pharmaceuticals. Appl. Organometal. Chem. 2005, 19, 1-10.
3. Gasser, G.; Ott, I.; Metzler-Nolte, N. Organometallic anticancer compounds. J. Med. Chem. 2011, 54, 3-25.
4. Casini, A.; Gabbiani, C.; Sorrentino, F.; Rigobello, M.P.; Bindoli, A.; Geldbach, T.J.; Marrone, A.; Re, N.; Hartinger, C.G.; Dyson, P.J.; et al. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)- arene compounds. J. Med. Chem. 2008, 51, 6773-6781.
5. Page, S. Ruthenium compounds as anticancer agents. Education in Chemistry 2012. Available online: http://www.rsc.org/eic (accessed on 1 August 2012).
6. Allardyce, C.S.; Dyson, P.J. Ruthenium in medicine: Current clinical uses and future prospects. Platium Metal 2001, 45, 62-69.
7. Heffeter, P.; Bock, K.; Atil, B.; Hoda, M.A.R.; Korner, W.; Bartel, C.; Jungwirth, U.; Keppler, B.K.; Micksche, M.; Berger, W.; et al. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. J. Biol. Inorg. Chem. 2010, 15, 737-748.
8. Chatterjee, S.; Kundu, S.; Bhattacharyya, A.; Hartinger, C.G.; Dyson, P.J. The ruthenium(II)- arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J. Biol. Inorg. Chem. 2008, 13, 1149-1155.
9. Hartinger, C.G.; Jakupec, M.A.; Zorbas-Seifried, S.; Groessl, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P.J.; Keppler, B.K. KP1019, A new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients. Chem. Biodiver. 2008, 5, 2140-2155.
10. Wu, B.; Ong, M.S.; Groessl, M.; Adhireksan, Z.; Hartinger, C.G.; Dyson, P.J.; Davey, C.A. A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core. Chem. Eur. J. 2011, 17, 3562-3566.
11. Ang, W.H.; Daldini, E.; Scolaro, C.; Scopelliti, R.; Juillerat-Jeannerat, L.; Dyson, P.J. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis. Inorg. Chem. 2006, 45, 9006-9013.
12. Egger, A.E.; Hartinger, C.G.; Renfrew, A.K.; Dyson, P.J. Metabolization of [Ru(η6-C6H5CF3)(pta)Cl2]: A cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand. J. Biol. Inorg. Chem. 2010, 15, 919-927.
13. Wu, A.; Dehestani, A.; Saganic, E.; Crevier, T.J.; Kaminsky, W.; Cohen, D.E.; Mayer, J.M. Reactions of Tp-Os nitrido complexes with the nucleophiles hydroxide and thiosulfate. Inorg. Chim. Acta 2006, 359, 2842-2849.
14. Richardson, D.E.; Lang, G.H.L.; Crestoni, E.; Ryan, M.F.; Eyler, J.R. Intrinsic reactivity of metal- hydroxide complexes: O-H bond activation and adduct formation in gas-phase reactions of Cp2ZrOH+. Int. J. Mass Spectrom. 2001, 204, 255-266.
15. Shubina, E.S.; Belkova, N.V.; Epstein, L.M. Novel types of hydrogen bonding with transition metal pi-complexes and hydrides. J. Organomet. Chem. 1997, 536-537, 17-29.
16. Hoskin, A.J.; Stephan, D.W. Early transition metal hydride complexes: Synthesis and reactivity. Coord. Chem. Rev. 2002, 233-234, 107-129.
17. Heinekey, D.M.; Mellows, H.; Pratum, T. Dynamic Processes in cis-dihydrogen/hydride complexes of ruthenium. J. Am. Chem. Soc. 2000, 122, 6498-6499.
18. Lee, D.; Lippard, S.J. Structural flexibility within a sterically hindered ligand platform: mononuclear iron(II) carboxylate complexes as subsite models for diiron(II) centers. Inorg. Chim. Acta 2002, 341, 1-11.
19. Kannan, S.; Venkatachalam, G.; Lee, H.; Min, B.K.; Kim, W.; Koo, E.; Do, Y.R.; Yoon, S. Mononuclear transition metal complexes with sterically hindered carboxylate ligands: Synthesis, structural and spectral properties. Polyhedron 2011, 30, 340-346.
20. Kaplan, A.W.; Ritter, J.C.M.; Bergman, R.G. Synthesis and structural characterization of late transition metal parent amido (LnM-NH2) complexes: An acid/conjugate base metathesis approach. J. Am. Chem. Soc. 1998, 120, 6828-6829.
21. Ciancetta, A.; Genheden, S.; Ryde, U. A QM/MM study of the binding of RAPTA ligands to cathepsin B. J. Comput. Aided Mol. Des. 2011, 25, 729-742.
22. Hanif, M.; Henke, H.; Meier, S.M.; Martic, S.; Labib, M.; Kandioller, W.; Jakupec, M.A.; Arion, V.B.; Kraatz, H.; Keppler, B.K.; et al. Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter? Inorg. Chem. 2010, 49, 7953-7963.
23. Turel, I.; Kljun, J.; Perdih, F.; Morozova, E.; Bakulev, V.; Kasyanenko, N.; Byl, J.A.W.; Osheroff, N. First ruthenium organometallic complex of antibacterial agent ofloxacin. Crystal structure and interactions with DNA. Inorg. Chem. 2010, 49, 10750-10752.
24. Xie, P.; Streu, C.; Qin, J.; Bregman, H.; Pagano, N.; Meggers, E.; Marmorstein, R. The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase. Biochemistry 2009, 48, 5187-5198.
25. Hu, W.; Luo, Q.; Ma, X.; Wu, K.; Liu, J.; Chen, Y.; Xiong, S.; Wang, J.; Sadler, P.J.; Wang, F. Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes. Chem. Eur. J. 2009, 15, 6586-6594.
26. Stepanenko, I.N.; Casini, A.; Edafe, F.; Novak, M.S.; Arion, V.B.; Dyson, P.J.; Jakupec, M.A.; Keppler, B.K. Conjugation of organoruthenium(II) 3-(1H-benzimidazol-2-yl)pyrazolo[3,4- b]pyridines and Indolo[3,2-d]benzazepines to recombinant human serum albumin: A strategy to enhance cytotoxicity in cancer cells. Inorg. Chem. 2011, 50, 12669-12679.
27. Zhuang, W.; Wu, X.; Zhou, Y.; Liu, G.; Wu, T.; Yao, X.; Du, L.; Wei, M. Polymorphisms of thymidylate synthase in the 5'- and 3' -untranslated regions and gastric cancer. Dig. Dis. Sci. 2009, 54, 1379-1385.
28. Berg, J.M.; Tymoczko, J.L.; Stryer, L. Biochemistry, 5th ed.; W.H. Freeman: New York, NY, USA, 2002.
29. Malla, R.R.; Gopinath, S.; Gondi, C.S.; Alapati, K.; Dinh, D.H.; Tsung, A.J.; Rao, J.S. uPAR and cathepsin B down regulation induces apoptosis by targeting calcineurin A to BAD via Bcl-2 in glioma. J. Neurooncol. 2012, 107, 69-80.
30. Hu, X.; Shelver, W.H. Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction. J. Mol. Graphics Model. 2003, 22, 115-126.
31. Adeniyi, A.A.; Ajibade, P.A. Inhibitory activities and possible anticancer targets of Ru(II)-based complexes using computational docking method. J. Mol. Graph. Model. 2012, 38, 60-69.
32. Granovsky, A.A. Firefly version 7.1.G. Available online: http://classic.chem.msu.su/gran/firefly/ index.html (accessed on 5 July 2012).
33. Caballero, N.A.; Meléndez, F.J.; Niño, A.; Muñoz-Caro, C. Molecular docking study of the binding of aminopyridines within the K+ channel. J. Mol. Model. 2007, 13, 579-586.
34. Ma, D.-L.; Ma, V.P.-Y.; Chan, D.S.-H.; Leung. K.-H.; Zhong, H.-J.; Leung, C.-H. In silico screening of quadruplex-binding ligands. Methods 2012, 57, 106-114.
35. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
36. Wang, F.; Habtemariam, A.; van der Geer, E.P.L.; Fernandez, R.; Melchart, M.; Deeth, R.J.; Aird, R.; Guichard, S.; Fabbiani, F.P.A.; Lozano-Casal, P.; et al. Controlling ligand substitution reactions of organometallic complexes: Tuning cancer cell cytotoxicity. PNAS 2005, 102, 18269-18274.
37. Research collaboratory for structural bioinformatics (RCSB) online pdb database. Available online: http://www.rcsb.org (accessed on 1 May 2012).
38. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch. G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605-1612.
39. Cole, J.C.; Nissink, J.W.M.; Taylor, R. Protein-ligand Docking and Virtual Screening with GOLD in Virtual Screening in Drug Discovery; Shoichet, B., Alvarez, J., Eds.; Taylor & Francis CRC Press: Boca Raton, FL, USA, 2005.
40. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. "Autodock4 and AutoDockTools4: Automated docking with selective receptor flexiblity". J. Comput. Chem. 2009, 30, 2785-2791.
41. Autodock. Available online: http://autodock.1369657.n2.nabble.com/ADL- Parameters-fordocking- with-metal-ions-in-receptor-td2505649.html (accessed on 6 May 2012).
42. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shaw, D.E.; Shelley, M.; et al. Glide: A new approach for rapid, Accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
43. Jacobson, M.P.; Pincus, D.L.; Rapp, C.S.; Day, T.J.F.; Honig, B.; Shaw, D.E.; Friesner, R.A. A hierarchical approach to all-atom protein loop prediction. Proteins 2004, 55, 351-367.
44. The R project for statistical computing. Available online: http://www.R-project.org (accessed 1 May 2012).